Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=27000958
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\27000958
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Nat+Rev+Clin+Oncol
2016 ; 13
(6
): 370-83
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Driving CAR T-cells forward
#MMPMID27000958
Jackson HJ
; Rafiq S
; Brentjens RJ
Nat Rev Clin Oncol
2016[Jun]; 13
(6
): 370-83
PMID27000958
show ga
The engineered expression of chimeric antigen receptors (CARs) on the surface of
T cells enables the redirection of T-cell specificity. Early clinical trials
using CAR T cells for the treatment of patients with cancer showed modest
results, but the impressive outcomes of several trials of CD19-targeted CAR T
cells in the treatment of patients with B-cell malignancies have generated an
increased enthusiasm for this approach. Important lessons have been derived from
clinical trials of CD19-specific CAR T cells, and ongoing clinical trials are
testing CAR designs directed at novel targets involved in haematological and
solid malignancies. In this Review, we discuss these trials and present
strategies that can increase the antitumour efficacy and safety of CAR T-cell
therapy. Given the fast-moving nature of this field, we only discuss studies with
direct translational application currently or soon-to-be tested in the clinical
setting.
free
free
free
